exRNAdisease

Entry Detail

---



General Information

Database ID: exR0274652 RNA Name: hsa-miR-22-3p RNA Type: miRNA Chromosome: chr17 Starnd: - Coordinate: Start Site(bp): 1713914 End Site(bp): 1713935 External Links: hsa-miR-22-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE22981 Description: Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: Early satge breast cancer Case Sample: Breast Cancer Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand CCDC97 chr19 41310172 41324873 + AP1S1 chr7 101154456 101161596 + RCOR1 chr14 102592649 102730561 + RAB11FIP4 chr17 31391675 31538211 + PPIF chr10 79347469 79355334 + FBXL19 chr16 30923055 30948783 + FNBP4 chr11 47716494 47767443 - DCP1A chr3 53283429 53347586 - GDAP1 chr8 74321130 74488872 + WSB2 chr12 118032694 118062430 - ITGA5 chr12 54395261 54419266 - IRS2 chr13 109752695 109786583 - FOXP1 chr3 70952817 71583993 - TMEM179B chr11 62787402 62790400 + ETS1 chr11 128458761 128587558 - ATP2C1 chr3 130850595 131016712 + ZNF740 chr12 53180704 53195142 + CACUL1 chr10 118674167 118755249 - ATP6V0B chr1 43974487 43978295 + ACLY chr17 41866917 41930542 - CLASP1 chr2 121337776 121649587 - PRLR chr5 35048756 35230487 - PDPR chr16 70113626 70162537 + WWC2 chr4 183099257 183320777 + TAGLN chr11 117199370 117207464 + BCL9 chr1 147541501 147626216 + GLIS2 chr16 4314761 4339597 + GBF1 chr10 102245532 102382899 + PDSS1 chr10 26697701 26746798 + RANBP2 chr2 108719482 108785809 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001699 chr7 40027197 40041630 + hsa_circ_0001414 chr4 56277780 56284152 + hsa_circ_0000733 chr17 1561546 1562030 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC021078.1 chr5 149494314 149504670 - AL360012.1 chr1 28648600 28648730 + MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - OIP5-AS1 chr15 41283990 41309737 + SNHG16 chr17 76557764 76565348 + Display:

Experiment Detail

GEO ID: GSE22981 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 801 Sample treatment protocol: NA RNA Extract protocol: Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications. RNA library preparation protocol: Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).

Reference

PMID: 21060830 Title: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer Author: Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer. Journal: PLoS One. 2010 Oct 29;5(10):e13735. Description: The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.